News Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD Continue Reading Previous Letter to Shareholders and Corporate UpdateNext Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023 Related Stories News BlackLine Opens New Birmingham Office at 10 Brindleyplace News Inuvo Releases New Investor Presentation News VersusMedia Launches Festival API to Help Developers and Filmmakers Discover Active Film Festivals Worldwide. News Intuitive.ai Earns AWS AI Competency Status News CertiK Hack3D: H1 2026 Report Reveals Over $1.31 Billion Lost to Web3 Security Incidents in the First Half of 2026 News MailSPEC Unveils CommuniGate SPEC 8.1: Reclaiming Communication Sovereignty for the “Sovereign Cloud” Era
